PMID: 19584153

Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Clin Cancer Res. 2009 Jul 15;15(14):4750-8. Epub 2009 Jul 7., 2009-07-15 [PubMed]
Sentences
No. Mutations Sentence Comment
201 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 19584153:201:43
status: VERIFIED
view ABCG2 p.Gln141Lys details
 Gardner et al. reported that the ABCG2 SNP Q141K (rs2231142 in the current article) is associated with the intracellular level of imatinib in vitro model (6). Login to comment 203 ABCG2 p.Val12Met
X
ABCG2 p.Val12Met 19584153:203:41
status: VERIFIED
view ABCG2 p.Val12Met details
 In the present study, the ABCG2 genotype V12M (rs2231137) was found to be significantly associated with cytogenetic response to imatinib therapy. Login to comment 204 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 19584153:204:77
status: VERIFIED
view ABCG2 p.Gln141Lys details
 Similar to a previous result using an in vitro model (6), the ABCG2 genotype Q141K (rs2231142) was associated with molecular response to imatinib therapy in univariate analyses although it was not statistically significant in multivariate analyses. Login to comment